<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01052597</url>
  </required_header>
  <id_info>
    <org_study_id>SWUEC30/2550</org_study_id>
    <nct_id>NCT01052597</nct_id>
  </id_info>
  <brief_title>Curcumin for Type 2 Diabetic Patients</brief_title>
  <official_title>Antiatherogenic and Antimetabolic Effect of Curcumin in Type 2 Diabetic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Srinakharinwirot University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, Thailand</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Srinakharinwirot University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      There are evidence that there is an association between insulin resistance and prolonged
      hyperinsulinemia or hyperglycemia in Type 2 diabetic patients. This will trigger oxidative
      stress system via reactive oxygen species (ROS) and lead to a high level of Nitric oxide.
      This can contribute to a significant change in blood vessel and could end up with the
      complications from cardiovascular disease and increased mortality rate of type 2 diabetic
      patients. The purpose of the present study was to examine the effectiveness of the curcumin
      in type 2 diabetic patients on the reduction of atherosclerosis events by examining
      pulse-wave velocity (PWV) and plasma high-sensitivity C-reactive protein (CRP) test and on
      blood sugar lowering, glycosylated hemoglobin (HBA1c), lipid profile, and insulin resistance.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2009</start_date>
  <completion_date type="Anticipated">March 2010</completion_date>
  <primary_completion_date type="Anticipated">February 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>to determine the effectiveness of curcumin on reduction of atherosclerotic events and risks in Type 2 diabetic patients</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To examine the effectiveness of curcumin on the reduction of blood sugar, glycosylated hemoglobin (HBA1c), lipid profile, and insulin resistance</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <condition>Cardiovascular Abnormalities</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Curcumin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>curcumin</intervention_name>
    <description>Curcumin capsule contains 250 mg curcuminoids, 2 capsule per time, 3 times a day for 12 months</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Curcumin</arm_group_label>
    <other_name>Manufactured by Government Pharmaceutical Organization, Thailand</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diabetic patients aged 35 years or older and did not use insulin during the first 5
             years of treatment after being diagnosed (with or without symptoms listed in the
             following inclusion criteria)

          -  Patient with hyperlipidemia (Cholesterol ≥ 200 mg/dl, TG ≥ 150 mg/dl, LDL ≥ 100 mg/dl
             and HDL ≥ 35 mg/dl)

          -  Patient with hypertension (Blood pressure ≥ 130/85 mmHg or take hypertensive drugs)

          -  Obesity (BMI ≥ 25)

        Exclusion Criteria:

          -  Current diagnosis of secondary peripheral arterial disease (PAD) (except listed in the
             inclusion criteria item 1-4)

          -  Current diagnosis of cardiovascular disease, i.e., coronary arterial disease and
             cerebrovascular disease

          -  Current diagnosis of end stage renal function with serum creatinine &gt; 2.0 mg/dl or on
             renal dialysis

          -  Current diagnosis of cirrhosis with ALT ≥ 3 times of normal range
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Somlak Chuengsamarn, Medical Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Srinakarinwirot University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Somlak Chuengsamarn, Medical Doctor</last_name>
    <phone>+6637-39-5085</phone>
    <email>somlukc@swu.ac.th</email>
  </overall_contact>
  <location>
    <facility>
      <name>HRH Princess Maha Chakri Sirindhorn Medical Center</name>
      <address>
        <city>Ongkarak</city>
        <state>Nakornnayok</state>
        <zip>26120</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Somlak Chuengsamarn, Medical Doctor</last_name>
      <phone>+6637-39-5085</phone>
      <email>somlukc@swu.ac.th</email>
    </contact>
    <investigator>
      <last_name>Somlak Chuengsamarn, Medical Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>August 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 19, 2010</study_first_submitted>
  <study_first_submitted_qc>January 19, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 20, 2010</study_first_posted>
  <last_update_submitted>January 19, 2010</last_update_submitted>
  <last_update_submitted_qc>January 19, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 20, 2010</last_update_posted>
  <responsible_party>
    <name_title>Assist.Prof. Somlak Chuengsamarn</name_title>
    <organization>Department of Internal Medicines, Faculty of Medicine, Srinakarinwirot University</organization>
  </responsible_party>
  <keyword>Type 2 diabetes</keyword>
  <keyword>Metabolic syndrome</keyword>
  <keyword>cardiovascular risk</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Cardiovascular Abnormalities</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Curcumin</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>July 29, 2010</submitted>
    <returned>August 24, 2010</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

